Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Gastrointestinal 1

Conditions

Stomach Neoplasms 15Gastric Adenocarcinoma 2Adenocarcinoma 2Recurrence 1Peritoneal Neoplasms 1Margins of Excision 1Locally Advanced Gastric Carcinoma 1Locally Advanced Gastric Cancer 1Advanced Gastric Cancer 1

Interventions

Oxaliplatin 46Gemcitabine 45Fluorouracil 40Capecitabine 31pembrolizumab 29Leucovorin 29Docetaxel 27Cisplatin 25Paclitaxel 23Irinotecan 18Carboplatin 18Bevacizumab 18130-nm albumin-bound paclitaxel 17Pemetrexed 15Albumin-Bound Paclitaxel 15Radiotherapy 14Nivolumab 12Ramucirumab 11Cyclophosphamide 11Trastuzumab 8Erlotinib Hydrochloride 8Taxes 7Radiosurgery 7Drug Therapy 7cemiplimab 6zolbetuximab 5trastuzumab deruxtecan 5regorafenib 5durvalumab 5Sorafenib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Adenocarcinoma × Gastrectomy × Clear all
NCT03013010 2025-12-08

PREACT

Shanghai Cancer Hospital, China

Phase 3 Completed
204 enrolled
Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT01523015 2013-02-05

Efficacy and Safety Study of the Combined Modality Therapy in Adenocarcinoma of the Esophago-gastric Junction

Medical University of Lublin

Phase 2/3 Unknown
100 enrolled
Tumor-Agnostic

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡